People · Operator
Named in public records as an officer, director or promoter · active 2016–2025 · Biotechnology, Other Health Care, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cardurion Pharmaceuticals, Inc. | — | Biotechnology | Series D+ | $431.7M | $2.8B | 2019 |
| X4 Pharmaceuticals, Inc | — | Biotechnology | Series C | $320.3M | $494.8M | 2016 |
| Fractyl Laboratories Inc. | — | Other Health Care | Series C | $290.1M | $309.5M | 2020 |
| Lyndra, Inc. | — | Biotechnology | Series D+ | $281.9M | $1.6B | 2021 |
| Glympse Bio, Inc. | — | Biotechnology | Series C | $114.0M | $324.7M | 2020 |
| Volastra Therapeutics, Inc. | — | Biotechnology | Series C | $105.3M | $170.5M | 2023 |
| Sequelae, Inc. | — | Other Technology | Series C | $80.2M | $1.4M | 2023 |
| Noetik Inc. | — | Biotechnology | Series B | $48.0M | $275.2M | 2024 |
| Amagma, Inc. | — | Biotechnology | Series B | $28.6M | $138.7M | 2020 |
| Quentis Therapeutics, Inc. | — | Biotechnology | Series B | $22.7M | $780.9M | 2018 |
| Suono Bio, Inc. | — | Biotechnology | Series A | $14.0M | $4.0M | 2017 |
Amy Schulman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Amy Schulman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Langer | 3 | 36 |
| Stanley Lapidus | 2 | 7 |
| Tillman U. Gerngross | 2 | 5 |
| Tillman Gerngross | 2 | 5 |
| Carl Gordon | 1 | 24 |
| Hemant Taneja | 1 | 21 |
| Michael Ross | 1 | 18 |
| Robert S Langer | 1 | 14 |
| Ajay Royan | 1 | 13 |
| Edward Mathers | 1 | 12 |
| Terrance McGuire | 1 | 9 |
| George Zachary | 1 | 9 |
| Theresia Gouw | 1 | 8 |
| Gregory Johnson | 1 | 8 |
| Alexandra Cantley | 1 | 8 |
| Brian H. Dovey | 1 | 7 |
| CARL L. GORDON | 1 | 7 |
| Daniel Lynch | 1 | 7 |
| Brian Dovey | 1 | 7 |
| Carlo Rizzuto | 1 | 7 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.